Krystal BiotechKRYS
KRYS
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
72% more call options, than puts
Call options by funds: $63.3M | Put options by funds: $36.8M
0% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 6 (+0) [Q4]
4% less repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 97
1.48% less ownership
Funds ownership: 98.03% [Q3] → 96.55% (-1.48%) [Q4]
6% less funds holding
Funds holding: 279 [Q3] → 262 (-17) [Q4]
15% less capital invested
Capital invested by funds: $5.13B [Q3] → $4.35B (-$776M) [Q4]
24% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 50
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$215
17%
upside
Avg. target
$223
21%
upside
High target
$245
33%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Jefferies Roger Song 24% 1-year accuracy 4 / 17 met price target | 33%upside $245 | Buy Initiated | 5 Mar 2025 |
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 89 / 415 met price target | 20%upside $221 | Buy Reiterated | 28 Feb 2025 |
Citigroup Yigal Nochomovitz 19% 1-year accuracy 8 / 43 met price target | 17%upside $215 | Neutral Maintained | 20 Feb 2025 |
Cantor Fitzgerald Josh Schimmer 22% 1-year accuracy 12 / 54 met price target | 17%upside $215 | Overweight Reiterated | 20 Feb 2025 |
Chardan Capital Geulah Livshits 14% 1-year accuracy 8 / 58 met price target | 19%upside $218 | Buy Maintained | 20 Feb 2025 |
Financial journalist opinion
Based on 6 articles about KRYS published over the past 30 days
Positive
Seeking Alpha
6 days ago
Krystal Biotech: Preparing To Chase Following Positive CHMP Opinion For VYJUVEK
Krystal Biotech's VYJUVEK, a first-mover gene therapy for DEB, has received a positive CHMP recommendation, potentially boosting its global market presence and valuation. Despite KRYS's premium valuation, its growth potential, strong financials, and first-mover advantage justify the market's appraisal, with a fair value estimate of $175-$185 per share. Key risks include regulatory setbacks, reimbursement issues, competition from Abeona's EB-101, and high operational expenses, which could impact short-term valuation and cash flow.
Positive
Zacks Investment Research
1 week ago
Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Positive
Zacks Investment Research
1 week ago
Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Zacks Investment Research
3 weeks ago
Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?
KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
Positive
Zacks Investment Research
3 weeks ago
Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?
KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
Positive
Zacks Investment Research
3 weeks ago
KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug
Krystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU.
Neutral
GlobeNewsWire
1 month ago
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA's) announcement that its Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the European Commission (EC) to approve VYJUVEK® (beremagene geperpavec-svdt, or B-VEC) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. The CHMP's positive opinion includes support for administration of VYJUVEK in either a health care setting (e.g.
Positive
Zacks Investment Research
1 month ago
Why Krystal Biotech (KRYS) Might be Well Poised for a Surge
Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Positive
Zacks Investment Research
1 month ago
Why Krystal Biotech, Inc. (KRYS) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Positive
Zacks Investment Research
1 month ago
Krystal Biotech (KRYS) Upgraded to Buy: Here's What You Should Know
Krystal Biotech (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Charts implemented using Lightweight Charts™